US court voids $2.5 billion verdict in Gilead/Merck patent dispute

19 February 2018
medical_legal_law_big

In a dramatic reversal of fortunes, a US District court in Delaware has rescinded a prior decision compelling Gilead Sciences (Nasdaq: GILD) to pay $2.5 billion in damages to Merck & Co (NYSE: MRK).

That verdict was reached in late 2016 when a court ruled the development of blockbuster hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) infringed patents held by its New Jersey, USA-based rival.

The 2009 patent in question was filed by Merck’s Idenix unit and covers a compound used in major treatments for hepatitis C.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical